Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer

Valerie J. Wiebe, Christopher C. Benz, Irving Shemano, Timothy B. Cadman, Michael W. DeGregorio

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

A multicenter phase I pharmacokineticstudy of a new triphenylethylene antiestrogen, toremifene, was examined in 70 patients with advanced breast cancer. Patients were randomized to receive single daily oral doses of either 10, 20, 40, 60, 200, or 400 mg for 8 weeks. Plasma toremifene and its major metabolites, N-desmethyltoremifene and 4-hydroxytoremifene, were determined weekly during therapy and at 0, 7, 14, and 21 days after the discontinuation of therapy. The time to reach steady-state plasma concentrations was between 1 and 5 weeks, with steady-state being achieved earlier (1-2 weeks) at daily doses of 200 and 400 mg. The time to peak concentration following oral doses of toremifene ranged from 1.5 to 4.5 h. The terminal half-life of elimination was 5.0, 6.0, and 5.0 days for toremifene, desmethyltoremifene, and 4-hydroxytoremifene, respectively. Plasma concentrations of 4-hydroxytoremifene were detectable only at high doses (200 and 400 mg/day) of toremifene. The results of this phase I pharmacokinetic study show that toremifene has metabolic and kinetic patterns that are similar to those previously reported with tamoxifen.

Original languageEnglish (US)
Pages (from-to)247-251
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume25
Issue number4
DOIs
StatePublished - Jul 1990
Externally publishedYes

Fingerprint

Toremifene
Pharmacokinetics
Metabolites
Breast Neoplasms
Plasmas
Estrogen Receptor Modulators
Tamoxifen
Half-Life
Kinetics
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. / Wiebe, Valerie J.; Benz, Christopher C.; Shemano, Irving; Cadman, Timothy B.; DeGregorio, Michael W.

In: Cancer Chemotherapy and Pharmacology, Vol. 25, No. 4, 07.1990, p. 247-251.

Research output: Contribution to journalArticle

Wiebe, Valerie J. ; Benz, Christopher C. ; Shemano, Irving ; Cadman, Timothy B. ; DeGregorio, Michael W. / Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. In: Cancer Chemotherapy and Pharmacology. 1990 ; Vol. 25, No. 4. pp. 247-251.
@article{b73cbecdd7a148548c55240e31da6989,
title = "Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer",
abstract = "A multicenter phase I pharmacokineticstudy of a new triphenylethylene antiestrogen, toremifene, was examined in 70 patients with advanced breast cancer. Patients were randomized to receive single daily oral doses of either 10, 20, 40, 60, 200, or 400 mg for 8 weeks. Plasma toremifene and its major metabolites, N-desmethyltoremifene and 4-hydroxytoremifene, were determined weekly during therapy and at 0, 7, 14, and 21 days after the discontinuation of therapy. The time to reach steady-state plasma concentrations was between 1 and 5 weeks, with steady-state being achieved earlier (1-2 weeks) at daily doses of 200 and 400 mg. The time to peak concentration following oral doses of toremifene ranged from 1.5 to 4.5 h. The terminal half-life of elimination was 5.0, 6.0, and 5.0 days for toremifene, desmethyltoremifene, and 4-hydroxytoremifene, respectively. Plasma concentrations of 4-hydroxytoremifene were detectable only at high doses (200 and 400 mg/day) of toremifene. The results of this phase I pharmacokinetic study show that toremifene has metabolic and kinetic patterns that are similar to those previously reported with tamoxifen.",
author = "Wiebe, {Valerie J.} and Benz, {Christopher C.} and Irving Shemano and Cadman, {Timothy B.} and DeGregorio, {Michael W.}",
year = "1990",
month = "7",
doi = "10.1007/BF00684880",
language = "English (US)",
volume = "25",
pages = "247--251",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer

AU - Wiebe, Valerie J.

AU - Benz, Christopher C.

AU - Shemano, Irving

AU - Cadman, Timothy B.

AU - DeGregorio, Michael W.

PY - 1990/7

Y1 - 1990/7

N2 - A multicenter phase I pharmacokineticstudy of a new triphenylethylene antiestrogen, toremifene, was examined in 70 patients with advanced breast cancer. Patients were randomized to receive single daily oral doses of either 10, 20, 40, 60, 200, or 400 mg for 8 weeks. Plasma toremifene and its major metabolites, N-desmethyltoremifene and 4-hydroxytoremifene, were determined weekly during therapy and at 0, 7, 14, and 21 days after the discontinuation of therapy. The time to reach steady-state plasma concentrations was between 1 and 5 weeks, with steady-state being achieved earlier (1-2 weeks) at daily doses of 200 and 400 mg. The time to peak concentration following oral doses of toremifene ranged from 1.5 to 4.5 h. The terminal half-life of elimination was 5.0, 6.0, and 5.0 days for toremifene, desmethyltoremifene, and 4-hydroxytoremifene, respectively. Plasma concentrations of 4-hydroxytoremifene were detectable only at high doses (200 and 400 mg/day) of toremifene. The results of this phase I pharmacokinetic study show that toremifene has metabolic and kinetic patterns that are similar to those previously reported with tamoxifen.

AB - A multicenter phase I pharmacokineticstudy of a new triphenylethylene antiestrogen, toremifene, was examined in 70 patients with advanced breast cancer. Patients were randomized to receive single daily oral doses of either 10, 20, 40, 60, 200, or 400 mg for 8 weeks. Plasma toremifene and its major metabolites, N-desmethyltoremifene and 4-hydroxytoremifene, were determined weekly during therapy and at 0, 7, 14, and 21 days after the discontinuation of therapy. The time to reach steady-state plasma concentrations was between 1 and 5 weeks, with steady-state being achieved earlier (1-2 weeks) at daily doses of 200 and 400 mg. The time to peak concentration following oral doses of toremifene ranged from 1.5 to 4.5 h. The terminal half-life of elimination was 5.0, 6.0, and 5.0 days for toremifene, desmethyltoremifene, and 4-hydroxytoremifene, respectively. Plasma concentrations of 4-hydroxytoremifene were detectable only at high doses (200 and 400 mg/day) of toremifene. The results of this phase I pharmacokinetic study show that toremifene has metabolic and kinetic patterns that are similar to those previously reported with tamoxifen.

UR - http://www.scopus.com/inward/record.url?scp=0025136713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025136713&partnerID=8YFLogxK

U2 - 10.1007/BF00684880

DO - 10.1007/BF00684880

M3 - Article

VL - 25

SP - 247

EP - 251

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -